BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has successfully closed the fifth tranche of its private placement, raising $225,000 through the issuance of 4.5 million units to support its business plans. The funds will further the development of its recently acquired immunological assets, including those in oncology and infectious diseases. Additionally, BioVaxys has settled a debt with a consultant by issuing over 1.5 million shares.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
